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treatment failures in Djiboutian patients
Aden Elmi Abar1,2*, Asma Jlizi2, Houssein Youssouf Darar3, Mohamed Ali Ben Hadj Kacem2 and Amine Slim2Abstract: In this study we report the prevalence of antiretroviral drug resistant HIV-1 genotypes of virus isolated
from Djiboutian patients who failed first-line antiretroviral therapy (ART) and from ART naïve patients.
Patients and methods: A total of 35 blood samples from 16 patients who showed first-line ART failure (>1000 viral
genome copies/ml) and 19 ART-naïve patients were collected in Djibouti from October 2009 to December 2009.
Both the protease (PR) and reverse transcriptase (RT) genes were amplified and sequenced using National Agency
for AIDS Research (ANRS) protocols. The Stanford HIV database algorithm was used for interpretation of resistance
data and genotyping.
Results: Among the 16 patients with first-line ART failure, nine (56.2%) showed reverse transcriptase
inhibitor-resistant HIV-1 strains: two (12.5%) were resistant to nucleoside (NRTI), one (6.25%) to non-nucleoside
(NNRTI) reverse transcriptase inhibitors, and six (37.5%) to both. Analysis of the DNA sequencing data indicated that
the most common mutations conferring drug resistance were M184V (38%) for NRTI and K103N (25%) for NNRTI.
Only NRTI primary mutations K101Q, K103N and the PI minor mutation L10V were found in ART naïve individuals.
No protease inhibitor resistant strains were detected. In our study, we found no detectable resistance in 44% of
all patients who experienced therapeutic failure which was explained by low compliance, co-infection with
tuberculosis and malnutrition. Genotyping revealed that 65.7% of samples were infected with subtype C, 20% with
CRF02_AG, 8.5% with B, 2.9% with CRF02_AG/C and 2.9% with K/C.
Conclusion: The results of this first study about drug resistance mutations in first-line ART failures show the
importance of performing drug resistance mutation test which guides the choice of a second-line regimen. This
will improve the management of HIV-infected Djiboutian patients.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/2051206212753973
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Virological failureBackground
Since the discovery of human immunodeficiency virus
(HIV) as the causative agent in 1983, the HIV-1 pandemic
is characterized by an extensive variability and the circula-
tion of numerous genotypes and recombinant forms
(CRFs) [1,2]. Subtype C is the most prevalent, estimated* Correspondence: aden_elmi@yahoo.fr
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reproduction in any medium, provided the orto represent 48% infections in the HIV-1 pandemic [3].
Subtype C is predominant particularly in south and east
Africa [4]. This strongly contrasts with the situation in
central Africa where a marked genetic heterogeneity is
observed.
HIV-1 remains a crucial global health problem. Delivery
of ART in low and middle income countries has required
utilization of a public health approach in which standar-
dized, rather than individualized, regimens are prescribed
to very large numbers of HIV-1-infected individuals [5].
At present, the majority of individuals in these countries
are initiating first-line therapy with a non-nucleosideral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Elmi Abar et al. Diagnostic Pathology 2012, 7:138 Page 2 of 7
http://www.diagnosticpathology.org/content/7/1/138reverse transcriptase inhibitor (NNRTI) and two nucleo-
side reverse transcriptase inhibitors (NRTI) [6].
The introduction of antiretroviral (ARV) therapy in
resource-poor settings is effective in suppressing HIV-1
replication and prolonging life of infected individuals.
Nevertheless, patients in routine clinical care experience
sustain detectable viral replication even under potent
combination therapy. Various factors underlie this failure
to achieve viral suppression, but resistance to current
medications has been increasingly recognized as an im-
portant factor. Rational choice of the NRTI component
of second-line therapy should be based on patterns of
resistance developed during first-line therapy [7].
Djibouti is the smallest country in east Africa. The
estimated prevalence of HIV-1 infection was around
2.5% (2009). Since the introduction of antiretroviral ther-
apy in 2004, no data exist on the epidemiology of drug
resistance mutations and little was known about HIV-1
genotypes circulating in Djibouti. Data on drug resist-
ance in the routine care setting are urgently required to
check ART efficacy. The present study aims to
characterize circulating HIV-1 subtypes and to identify
drug resistance mutations in patients who first-line ther-
apy failed (>1000 copies/mL) and antiretroviral-naive
patients from Djibouti.
Materials and methods
Population study and sample collection
Between October and December 2009, the whole blood
samples were collected in Djibouti city from 35 HIV-1
infected patients consulting at three health centers (Hôpital
General Peltier, N=23, Centre Yonis Thoussaint, N=9 and
Centre Paul Faure, N=3). EDTA (ethylenediaminetetraace-
tic acid-anticoagulated) plasma specimens were obtained
after centrifugation, and stored at −80°C in aliquots for
later assessment of HIV RNA viral-load and genotypic
drug resistance testing. The ethical aspects of this study
were approved by the local committee. For all participants,
blood collection was performed after informed consent,
under the supervision of local sanitary authorities.
Viral load and CD4
The CD3/CD4+ cells were enumerated by flowcytome-
try (BD FACSCount System) and the quantification of
HIV-1 viral load (VL) was measured using NASBA,
NucliSENSWEasyQ Assays (BioMerieux) at the central
laboratory of “Hôpital General Peltier” in Djibouti.
The plasma samples were shipped to the Laboratory of
Microbiology of “Charles Nicolle” Hospital (Tunis, Tunisia)
for drug resistance genotyping tests.
Drug resistance genotyping
For Drug Resistance genotyping, the viral RNA was iso-
lated from plasma samples using DSP virus RNA kit(QIAGEN Inc.) and reverse transcribed to make com-
plementary DNA (cDNA) copies using a cDNA synthe-
sis kit the One Step RT-PCR (QIAGEN Inc). The
reverse transcriptase (RT) and protease (PR) genes were
amplified according to the ANRS consensus sets of pri-
mers: for the RT gene amplification, MJ3 and MJ4 pri-
mers were used for a first PCR (RT-PCR), and A(35)
with NE1(35) as inner primers for nested PCR. For the
protease gene amplification, 5′Prot1 and 3′Prot1 outer
primers were used and the 5′Prot2 and 3′Prot2 as
inner primers: (ANRS: http://www.hivfrenchresistance.
org/ANRS-procedures.pdf ).
RT-PCR involved a reverse transcription step at 50°C for
30 minutes, followed by 95°C for 15 minutes before pro-
ceeding to 40 cycles of 95°C for 45 seconds, 50°C for
30 seconds and 72°C for 1 minute 30 seconds, with a final
extension step of 10 minutes at 72°C. The RT-PCR pro-
ducts were then subjected to nested PCR with the follow-
ing cycling conditions: a denaturation step of 2 minutes at
95°C, and then 35 cycles with 1 cycle consisting of 30 sec-
onds at 95°C, 30 seconds at 55°C and 30 seconds at 72°C
with a final extension at 72°C for 7 minutes.
PCR products (5 μL) were resolved by electrophoresis
on a 1.5% agarose gel GellyPhorLE, (Euroclone, UK).
DNA bands were stained with RedSafe™ Nucleid Acid
Staining Solution [20,000X] (iNtRON Biotechnology, Inc,
Korea). They were then visualized in UV light to assess
the presence of fragments of the expected length com-
pared with the standard marker SharpMass™50-DNA
ladder (Euroclone, Wetherby, UK). The amplification
products were purified using QIAquick PCR Purification
kit (QIAGEN Inc).
The PCR products were finally sequenced on an
ABI3130 Genetic Analyser (Applied Biosystems), and
compared with HXB-2 sequence using SeqScape v2.6
software (Life technologies). All sequences were sub-
jected to quality assessment and determination of DR
mutation profile (susceptible, intermediate resistance
and resistance) using the Stanford Database (available at
http://hivdb.stanford.edu/).
Results
This study includes 35 HIV-1-infected Djiboutian patients
enrolled between October and December 2009. Their
mean age was 32.3 years. Among these patients, nineteen
patients were ART-naïve (54.2%) and 16 were first-line
ART failures (45.8%). In ART naïve patients, the median
CD4 count was 144 cells/μl and the average viral load was
5.58 log10/ml (388 643 copies/ml). For the patients with
first-line ART failure, the median CD4 count was 178
cells/μl, viral loads mean was 5.62 log10/ml and the me-
dian time of therapy was 30 months (Table 1). There were
20 females (57%) which were not pregnant at the time of
blood collection. Genetic subtyping revealed that 65.7% of
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CRF02_AG, 8.5% with B, 2.9% with CRF02_AG/C and
2.9% with K/C (Table 2).
The ART naïve patients showed only NNRTI-
associated mutations which were K103N (2 strains) and
K101Q (1). No mutations of NRTI were detected. The
minor PI mutation L10V was detected in one ART naïve
patient [8].
At the time of sampling, all the patients receiving ART
were treated by first line. According to the Djiboutian
National Program for fighting against AIDS (PNLS)
recommendations [9], the first-line treatment consists in
2 NRTI + 1NNRTI. The NRTI backbones were stavudine,
zidovudine, and lamivudine. The most used drug com-
bination (12 Patients (75%)) was AZT/3TC/EFV, while
the 6 other patients received either AZT/3TC/NVP,
D4T/3TC/EFV or D4T/3TC/NVP. The NRTI-associated
mutations were D67N (2 strains), T69N (1), M184V (6),
L210W (2), T215Y (2). The NNRTI-associated mutations
were K101Q (1), K103N (4), V179E (1), Y181C (1),
Y188L (2), G190A (2) (Table 3). For PI-associated muta-
tions, the minor mutation L10V and other polymorph-
ism were detected.
Drug susceptibility results were classified into three
categories: susceptible, intermediate resistance and re-
sistance. Of the 16 patients with first-line ART failure,
56.25% showed resistance to at least one antiretroviral
molecule: two patients (12.5%) were resistant to nucleo-
side (NRTI), one (6.25%) to non-nucleoside (NNRTI) re-
verse transcriptase inhibitors, and six (37.5%) to both.
We found that the resistance rates to Lamivudine and
Nevirapine in the 16 patients with first-line ART failure
were 37.5% and 43.75% respectively. Forty four percent
(44%) of sequences from viral strains did not show any
mutation associated to ARV drug resistance- 7out of 16
[10]. Therefore, therapeutic solutions using second line
drugs could be proposed to our patients with therapeutic
failure and drug resistance mutations.
Discussion
Minimizing drug resistance to highly active antiretroviral
therapy (HAART) is important. First, it maximizes the
opportunity for successful second-line and subsequent






Age (Mean, Years) 32 32.67
CD4 (cells/μl) Mean 144 178
CVp (log 10 copies/ml) Mean 5.58 5.62second, it limits the transmission of drug-resistant
viruses. We report results of the HIV-1 genetic diversity
and prevalence of mutations associated with antiretro-
viral drugs among ART naïve as well as patients who
failed first line therapy. The HAART was introduced in
Djibouti in 2004. Djibouti, surrounded by Eritrea, Ethiopia,
and Somalia, is an important crossroad for trade and
exchange.
Our result revealed a majority of subtype C (~66%). In
fact, Subtype C prevalence has been described in the
Horn of Africa[11-14] and a similar prevalence was pre-
viously reported in Djibouti in 2005 [15,16]. However,
our study describes the subtype B in Djibouti for the
first time. It is the predominant subtype in the Western
world and the clade that has circulated in North Amer-
ica and Europe. The detection of CRF02_AG strains
indicates that they are still circulating in Djibouti, the
only country in East Africa in which this recombinant
virus was found some years ago [17,18]. CRF02_AG re-
combinant isolates were primarily described in West and
Central Africa [19,20]. The discordances observed be-
tween RT and PR sequences in 2 isolates (CRF02_AG/C,
K/C) are probably attributable to the high variability of
the genome of HIV in particularly intra subtype recom-
bination within group M subtype C [21].
For the ART naïve patients, the low rate of CD4 and
the high rate of VL can be explain by the fact that 80%
of patients infected by HIV in Djibouti was already
detected at an advanced stage of the epidemic according
to WHO classification [22,23]. Among the 19 strains, 2
were resistant only to non-nucleoside reverse transcript-
ase inhibitors (NNRTIs) while one strain showed a
minor mutation to PI. Detection of RT and protease
mutations associated with drug resistance in individuals
who have not been exposed to antiretroviral therapy is
thought to result from either transmission from a trea-
ted individual.
Concerning first-line ART failures, 38% of 16 strains
sequenced in this group had the M184V mutation. This
mutation is selected by lamivudine (3TC), emtricitabine
(FTC) or abacavir (ABC) use and confers high-level resist-
ance to 3TC (Figure 1) [24]. Patients receiving incom-
pletely suppressive 3TC regimens usually develop M184V
as their first mutation [25,26]. Accumulation of the other
mutations observed included thymidine associated muta-
tions (including M41L, D67N, K70R, L210W, T215Y/F,
K219Q) results in increasing resistance to AZT, Tenofovir,
D4T, Abacavir, and DDI [27,28]. Two multidrug resistance
mutation profiles in general, confer high level drug resist-
ance to all NRTIs. The most common occurring nucleo-
tide excision mutations (NEMs) that confer resistance by
enhanced excision [29] were at position 215. The T215Y
mutation was observed in 13% of the sequences while
T215F was detected in 6%. Clinical studies have shown
Table 2 HIV-1 subtypes and distribution of resistance-associated mutations among 19 ART-naïve patients attending
three health centers in Djibouti city between October and December 2009
Patients SEX CD4 VL (cp/mL) SUBTYPE NRTI NNRTI Major Mutation PI Minor Mutation PI
1 M 208 170 000 C None None None None
2 M 107 4 690 000 C None None None None
3 F 186 1 600 000 CRFO2_AG None K103N None None
4 M 167 150 000 C None None None None
5 F 195 160 000 C None None None None
6 F 154 98 000 C None None None None
7 F 104 3 360 CRF02_AG None None None None
8 F 47 350 000 C None K101Q, K103N None None
9 M 126 76 000 CRFO2_AG None None None L10V
10 M 100 150 000 C None None None None
11 M 20 420 000 CRF02_AG None None None None
12 F 51 45 000 K/C None None None None
13 F 540 260 000 C None None None None
14 M 56 43 900 C None None None None
15 F 23 663 000 C None None None None
16 M 49 185 000 C None None None None
17 F 170 87 200 B None K101E None None
18 F 250 120 000 C None None None None
19 F 90 431 000 C None None None None
Table 3 HIV-1 subtypes and distribution of resistance-associated mutations among 16 patients with first-line ART
failure attending three health centers in Djibouti city between October and December 2009




20 F 62 C 630 000 AZT/3TC/EFV None None None None
21 M 92 C 220 000 AZT/3TC/EFV None None None None
22 F 346 C 1 900 AZT/3TC/EFV None None None None
23 M 176 C 21 000 AZT/3TC/EFV None None None None
24 F 220 C 3270 AZT/3TC/EFV None None None None
25 F 243 C 7 500 AZT/3TC/EFV None None None None
26 F 103 C 413 000 D4T/3TC/NVP None K101Q, Y181C None None
27 M 52 C 26 000 AZT/3TC/EFV M184V K103N None None
28 M 249 C 213 000 D4T/3TC/EFV D67N, M184V, L210W, T215Y Y188L, G190A None None





30 F 140 CRFO2_AG 168 000 D4T/3TC/EFV None None None None
31 F 250 CRF02_AG/C 72 720 AZT/3TC/NVP K70KR, M184V, K219R K103N None None
32 M 92 CRFO2_AG 21 000 AZT/3TC/EFV T69N V179E, Y188L None L10V
33 M 88 CRFO2_AG 7 100 AZT/3TC/EFV M184V K103N None L10V
34 F 208 B 1 300 D4T/3TC/NVP A62V None None None
35 M 105 B 4 837 560 AZT/3TC/EFV A62V, M184V, T215F, K219Q None None None
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Figure 1 Frequencies of resistance levels to nucleoside (NRTI) and non-nucleoside (NNRTI) reverse transcriptase inhibitors. The
horizontal bars indicates the frequency of susceptible (white), intermediate resistance (grey) and resistant (black) samples to NRTI and NNRTI
reverse transcriptase inhibitors.
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interfere with the clinical response to zidovudine, stavu-
dine, abacavir, didanosine, and most dual NRTI combina-
tions [30]. Mutations conferring resistance to NNRTIs
were also seen, with one strain showing resistance only to
NNRTIs. The NNRTI resistance-conferring mutations
included K103N (25%), Y188L (12.5%), Y181C (6%),
G190A (6%), H221Y (6%), M230L (6%). Our data suggest
the non-epidemic circulation of resistant viruses, and the
absence of multi-class drug resistant viral strains.
It is important to appreciate that resistance at failure
is only one factor to consider when choosing an initial
HAART regimen. Coformulation, simplicity of adminis-
tration, price, drug interactions (particularly with tuber-
culosis therapy), toxicity and adverse events are all
important considerations and will differ between patient
populations. We noticed seven patients (~44%) did not
show resistance-conferring mutations and the thera-
peutic failure may have been due to other factors
[31-35]. Information on treatment from their clinic
folders allowed us to confirm that for five of these seven
cases the ART failure profile was due to poor adherence
and for the remaining two cases the detectable viral level
was due to coinfection with tuberculosis and malnutri-
tion [36-38].The escalating rates of transmission of drug resistant
virus observed in the past few years, coupled with the
poorer response to treatment in persons with drug re-
sistant virus, are being considered as a basis for a recom-
mendation that resistance tests should be performed
routinely for persons with new HIV infection [39]. This
evaluation, both at the baseline and in follow-up, will be
crucial to assess the impact of therapy regimens on re-
sistance development and also their adequation.
Conclusion
This study reveals primary mutations that confer resist-
ance to NRTI, NNRTI in HIV-1 non-B and B subtype
strains, isolated from ART naïve as well as patients who
failed first line therapy in Djibouti. It also illustrates the
importance of preliminary surveys of drug-resistance
mutations in resource-poor countries. Therefore, we sug-
gest the use of resistance testing to check the prevalence
of the drug resistance mutation that arises following fail-
ure of the first line regimen. This will help in establishing
guidelines for second line regimens in Djibouti. This
allows the selection of adapted antiretroviral regimens in
these regions. Our results provide a basis for repeated epi-
demiological studies to measure the population effects of
HIV treatment programs over time.
Elmi Abar et al. Diagnostic Pathology 2012, 7:138 Page 6 of 7
http://www.diagnosticpathology.org/content/7/1/138Abbreviations
ART: Antiretroviral therapy; PR: Protease; RT: Reverse Transcriptase;
ARV: Antiretroviral.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AEA: wrote the manuscript, has made substantial contributions to acquisition
of data, or analysis and interpretation of data. AEA and AJ: participated in
data analysis and interpretation. HYD and MA BHK: revised the manuscript.
AS: proposed the idea, revised the manuscript and save final approval of the
version to be published. All authors read and approved the final manuscript.
Acknowledgments
We thank Ali Abdillahi, Nima Ahmed, Mohamed Miganeh, Houssein Yonis
and Yacin Ahmed for technical assistance from Djibouti. This work was
performed at the National HIV Reference Laboratory, Charles Nicolle Hospital,
Tunis, Tunisia. The expert assistance, Assistant Salma ABID, Mme Majda BEN
NASR of the laboratory staff is gratefully acknowledged.
Author details
1Laboratoire de la Caisse Nationale de Sécurité Sociale, Djibouti, Republic of
Djibouti. 2Laboratoire de Microbiologie, CHU Charles Nicolle, Tunis, Tunisie.
3Service des Maladies Infectieuses de l’Hôpital Général Peltier, Djibouti,
Republic of Djibouti.
Received: 24 June 2012 Accepted: 18 September 2012
Published: 8 October 2012
References
1. Robert S, Michael Gottlieb S, Robert S, Howard Schanker M, Joel D,
Weisman DO, Peng Thim F, Robert Wolf A, Andrew S: Pneumocystis carinii
Pneumonia and Mucosal Candidiasis in Previously Healthy Homosexual
Men — Evidence of a New Acquired Cellular Immunodeficiency. N Engl J
Med 1981, 305:1425–1431.
2. Barre-Sinoussi F, et al: Isolation of a T-lymphotropic retrovirus from a
patient at risk for acquired immune deficiency syndrome (AIDS). Science
1983, 220:868–871.
3. Hemelaar J, Gouws E, Ghys PD, Osmanov S: Global trends in molecular
epidemiology of HIV-1 during 2000–2007. AIDS 2011, 25:679–689.
4. Thomson MM, Perez-Alvarez L, Najera R: Molecular epidemiology of HIV-1
genetic forms and its significance for vaccine development and therapy.
Lancet Infect Dis 2002, 2:461–471.
5. Gilks CF, Crowley S, Ekpini R, et al: The WHO public-health approach to
antiretroviral treatment against HIV in resource-limited settings. Lancet
2006, 368(9534):505–510.
6. World Health Organization: Antiretroviral therapy for HIV infection in adults
and adolescents: recommendations for a public health approach. Geneva,
Switzerland: WHO, HIV Department; 2006. Available at: http://www.who.int/
hiv/pub/guidelines/artadultguidelines.pdf. Accessed 12 December 2007.
7. Gazzard BG, British HIV: Association guidelines for the treatment of
HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008,
9:563–608.
8. Vergne L, Peeters M, Mpoudi-Ngole E, Bourgeois A, Liegeois F, Toure-Kane
C, Mboup S, Mulanga-Kabeya C, Saman E, Jourdan J, Reynes J, Delaporte E:
Genetic diversity of protease and reverse transcriptase sequences in
non-subtype B human immunodeficiency virus type 1 strains: evidence
of many minor drug resistance mutations in treatment-naive patients.
J Cardiovasc Manag 2000, 38:3919–3925.
9. Guide d’utilisation des Antirétroviraux (ARV) chez l’adulte et l’adolescent en
République de DJIBOUTI: 2008. http://www.aidstar-one.com/sites/default/
files/treatment/national_treatment_guidelines/Djibouti_adult_guidelines_
2008.pdf.
10. Jlizi A, Ben Ammar A, El Gaaied A, Slim F, Tebourski M, Ben Mamou T, Ben
C, et al: Profile of drug resistance mutations among HIV-1-infected
Tunisian subjects failing antiretroviral therapy. Arch Virol 2008,
153:1103–1108.
11. Abecasis AB, Vandamme AM, Lemey P: Quantifying differences in the
tempo of human immunodeficiency virus type 1 subtype evolution.
J Virol 2009, 83:12917–12924.12. Nyombi BM, et al: Diversity of human immunodeficiency virus type 1
subtypes in Kagera and Kilimanjaro regions Tanzania. AIDS Res Hum
Retroviruses 2008, 24:761–769.
13. Abebe A, Lukashov VV, Pollakis G, Kliphuis A, Fontanet AL, Goudsmit J, Rinke
TF, de Wit TF: Timing of the HIV-1 subtype C epidemic in Ethiopia based
on early virus strains and subsequent virus diversification. AIDS 2001,
15:1555–1561.
14. Abebe A, Lukashov VV, Rinke De Wit TF, Fisseha B, Tegbaru B, Kliphuis A,
Tesfaye G, Negassa H, Fontanet AL, Goudsmit J, Pollakis G: Timing of the
introduction into Ethiopia of subcluster C′ of HIV type 1 subtype C.
AIDS Res Hum Retrovir 2001, 17:657–661.
15. Maslin J, Rogier C, Caron M, Grandadam M, Koeck JL, Nicand E:
Antiretroviral drug resistance among drug-naive HIV-1-infected
individuals in Djibouti (Horn of Africa). Antivir Ther 2005, 10:855–859.
16. Maslin J, Rogier C, Berger F, Khamil MA, Mattera D, Grandadam M, Caron M,
Nicand E: Epidemiology and genetic characterization of HIV-1 isolates in
the general population of djibouti (Horn of Africa). J Acquir Immune Defic
Syndr 2005, 39:129–132.
17. Faria NR, Suchard MA, Abecasis A, Sousa JD, Ndembi N, Bonfim I, Camacho
RJ, Vandamme AM, Lemey P: Phylodynamics of the HIV-1 CRF02_AG
clade in Cameroon. Infect Genet Evol 2012, 12(2):453–460.
18. Hemelaar J, et al: The origin and diversity of the HIV-1 pandemic. Trends
in Molecular Medicine 2011, 20:1–11.
19. Carr JK, Salminen MO, Albert J, Sanders-Buell E, Gotte D, Birx DL, McCutchan
FE: Full genome sequences of human immunodeficiency virus type 1
subtypes G and A/G intersubtype recombinants. Virology 1998,
247:22–31.
20. Cornelissen M, van Den Burg R, Zorgdrager F, Goudsmit J: Spread of
distinct human immunodeficiency virus type 1 AG recombinant lineages
in Africa. J Gen Virol 2000, 81:515–523.
21. Rousseau CM, Learn GH, Bhattacharya T, Nickle DC, Heckerman D, Senica C,
Christian B, Philip J, Goulder R, Bruce D, Walker Photini K, Korber BT, Mullins
JI: Extensive Intra-subtype Recombination in South African HIV-1
Subtype C Infections. J Virol 2007, 81(9):4492–4500.
22. Darar HY, Kibangou N, Mbuzenakamwe MJ, Goulan MA, Ibrahim IM:
Réponse au traitement antirétroviral chez les patients infectés par
le VIH-1 suivis au Centre Yonis Toussaint de Djibouti [Abstract].
5éme Conférence Francophone VIH/SIDA, Maroc 2010, 493(77):215.
28–31 March 2010.
23. Kibangou N: Prise en charge des patients sous traitement ARV à Djibouti
entre 2004 et 2009 [Abstract]. 5éme Conférence Francophone VIH/SIDA,
Maroc 2010, 578(88):237. 28–31 March 2010.
24. Johnson VA, Vincent C, Günthard HF, Roger P, Deenan P, Robert S, Wensing
AM, Richman DD: 2011 update of the drug resistance mutations in HIV-1.
Top Antivir Med 2011, 19:156–164.
25. Geretti AM: Clinical implications of HIV drug resistance to nucleoside and
nucleotide reverse transcriptase inhibitors. AIDS Rev 2006, 8:210–220.
26. Theys K, Deforche K, Libin P, Camacho RJ, Van Laethem K, Vandamme AM:
Resistance pathways of human immunodeficiency virus type 1 against
the combination of zidovudine and lamivudine. J Gen Virol 2010,
91:1898–1908.
27. Van Vaerenbergh K, Van Laethem K, Albert J, Boucher CA, Clotet B, Floridia
M, Gerstoft J, Hejdeman B, Nielsen C, Pannecouque C, Perrin L, Pirillo MF,
Ruiz L, Schmit JC, Schneider F, Schoolmeester A, Schuurman R, Stellbrink HJ,
Stuyver L, Van Lunzen J, Van Remoortel B, Van Wijngaerden E, Vella S,
Witvrouw M, Yerly S, De Clercq E, Destmyer J, Vandamme AM: Prevalence
and characteristics of multinucleoside-resistant human
immunodeficiency virus type 1 among European patients receiving
combinations of nucleoside analogues. Antimicrob Agents Chemother 2000,
44:2109–2117.
28. Coakley EP, Gillis JM, Hammer SM: Phenotypic and genotypic resistance
patterns of HIV-1 isolates derived from individuals treated with
didanosine and stavudine. AIDS 2000, 14:F9–F15.
29. Shafer RW: Genotypic testing for human immunodeficiency virus type 1
drug resistance. Clin Microbiol Rev 2002, 15:247–277.
30. Emanuele B, Ana PC M, Victor Moreschi N, Camila DA S, Karla A, Saito AO,
Mecatti MC, Santos MG, Pimentel CR, Larissa LG S, Cruz CR, de Noronha L:
Histomorphometric and immunohistochemical analysis of infectious
agents, T-cell subpopulations and inflammatory adhesion molecules in
placentas from HIV-seropositive pregnant women. Diagn Pathol 2011,
6(101):101. 24 October 2011.
Elmi Abar et al. Diagnostic Pathology 2012, 7:138 Page 7 of 7
http://www.diagnosticpathology.org/content/7/1/13831. Eholie SP, N’Dour CT, Cisse M, Bissagnene E, Girard PM: Observance of
antiretroviral treatments African specificities. Med Mal Infect 2006,
36:443–448.
32. Phillips AN, Dunn D, Sabin C, et al: UK Collaborative Group on HIV Drug
Resistance, UK CHIC Study Group. Long term probability of detection of
HIV-1 drug resistance after starting antiretroviral therapy in routine
clinical practice. AIDS 2005, 19:487–494.
33. Chesney MA, Ickovics J, Hecht FM, et al: Adherence: a necessity for
successful HIV combination therapy. AIDS 1999, 13(A):S271–S278.
34. Bangsberg DR, Charlebois ED, Grant RM, et al: High levels of adherence do
not prevent accumulation of HIV drug resistance mutations. AIDS 2003,
17:1925–1932.
35. Shah B, Walshe L, Saple DG, et al: Adherence to antiretroviral therapy and
virologic suppression among HIV-infected persons receiving care in
private clinics in Mumbai, India. Clin Infect Dis 2007, 44:1235–1244.
36. Ahmed AA, Katlama C, Ghosn J, Guiguet M, Costagliola D: Évaluation de
l’observance au traitement antirétroviral au sein d’une cohorte de 200
patients à Djibouti (2005). Eastern Mediterranean Health Journal 2007,
13(6):1286–1297.
37. Renoux E, Barreh Matan A, Sevre JP, et al: Tuberculose et infection VIH:
expérience du programme national de lutte antituberculeuse de
Djibouti: 1990–1996. Med Trop 2002, 62:171–176.
38. Acina E, Morand C, Mahdi A, Morand JJ: La malnutrition en République de
Djibouti: un problème majeur de santé publique. Revue de l’ISERST 1991,
5:11–15.
39. Little SJ, Holte S, Routy JP, et al: Antiretroviral-drug resistance among
patients recently infected with HIV. New Engl J Med 2002, 347:385–394.
doi:10.1186/1746-1596-7-138
Cite this article as: Elmi Abar et al.: HIV-1 drug resistance genotyping
from antiretroviral therapy (ART) naïve and first-line treatment failures
in Djiboutian patients. Diagnostic Pathology 2012 7:138.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
